The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...
Treatment strategies for HHT are limited to symptom management as there are currently no approved therapeutics for the disease. “DIAG723 represents a powerful new approach to treating HHT, supported ...
PITTSBURGH (KFSN) -- HHT is a genetic disorder of the blood vessels. In severe cases, it can lead to sudden bleeding or stroke. Researchers say HHT affects more than one in 5,000 people, but 90 ...
Wednesday, September 18, 2024, CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare ...
Please provide your email address to receive an email when new articles are posted on . Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated ...
Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated IDA management, this series of Ace the Case sessions will highlight key teaching points ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results